All articles
Regulation & Policy

RFK Jr., the FDA, and BPC-157: What the 2026 Regulatory Reversal Means for Peptide Access

After years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.

April 25, 20269 min read
RFK Jr., the FDA, and BPC-157: What the 2026 Regulatory Reversal Means for Peptide Access

After years of FDA crackdowns on research peptides, a significant regulatory reversal in 2026 has changed the landscape for BPC-157, TB-500, and MOTS-C. Here's what actually happened and what it means for you.

Peptide South Africa Research Research TeamEditorial

#MOTS-C#FDA#Research Peptides#TB-500#Peptide Regulation#Compounding Pharmacies#Policy#RFK Jr.#BPC-157Share this articleTwitterLinkedInTrack Your Peptide Protocols

Use Peptide South Africa Research to log injections, calculate doses, access our peptide library, and optimize your protocols.

Download Peptide South Africa ResearchExplore More Peptide ResourcesFree peptide calculators·Peptide research hub·Peptide glossary·Semaglutide guide·BPC-157 guide·Best peptide calculator

Research disclaimer: Peptides discussed are for research and educational purposes only. They are not approved for human consumption unless specifically noted as FDA-approved medications. Always consult a qualified healthcare professional.